WINNIPEG, MANITOBA -- (MARKET WIRE) -- November 17, 2006 -- Medicure Inc. (TSX: MPH)(AMEX: MCU), a cardiovascular focused biopharmaceutical company, today announced it has commenced enrollment in the MEND-CABG II study. This single confirmatory Phase III study for registration will evaluate the cardioprotective effects of the Company’s FDA Fast Tracked product, MC-1, in approximately 3,000 patients undergoing coronary artery bypass graft (CABG) surgery.
